MedTrace Logo

Community Based Trial for AMEVIVE®

NCT00168753 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2014-09-08

No results posted yet for this study

Summary

To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.

Conditions

  • Moderate to Severe Chronic Plaque Psoriasis

Interventions

DRUG

Alefacept

IM

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Michael Gold · GoldSkin Care

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-03-31
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168753 on ClinicalTrials.gov